HSA — authorised 9 May 2023
- Marketing authorisation holder: CHIESI FARMACEUTICI S.P.A
- Status: likely_approved
🇸🇬 Elfabrio in Singapore
HSA authorised Elfabrio on 9 May 2023
Marketing authorisation
Elfabrio in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in Singapore
Frequently asked questions
Is Elfabrio approved in Singapore?
Yes. HSA authorised it on 9 May 2023.
Who is the marketing authorisation holder for Elfabrio in Singapore?
CHIESI FARMACEUTICI S.P.A holds the Singaporean marketing authorisation.